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The human papillomavirus (HPV) was detected in 20 (29%) out of 69 lung carcinomas (LCs) in Chile, by PCR and Southern blot, and
was more frequently detected in squamous cell carcinoma (SQC) than in adenocarcinomas (46 vs 9%, P¼0.001). HPV-16, positive in
11 cases, was the most frequently detected HPV genotype determined by DNA sequencing. HPV-16 E2/E6 ratio, estimated from
real-time PCR analysis, was much lower than the unity, suggesting that at least a partial HPV-16 genome was integrated in all but one
HPV-16-positive SQCs. The remaining one case was suspected to have only episomal HPV-16. Although the viral load was low in
most of the LCs, a case showed the HPV-16 copy number as high as 8479 per nanogram DNA, which was even a few times higher
than the minimum viral load of seven cervical carcinomas (observed viral load: 3356–609392 per nanogram DNA). The expression
of the HPV-16/18 E6 protein was found in only two HPV-16-positive SQCs (13%) but not in the case with the highest viral load.
Although the viral load was in general very low and HPV E6 expression is none or weak, further studies seem warranted to examine
aetiological involvement of high-risk HPV in lung carcinogenesis.
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The human papillomavirus (HPV) is an epitheliotropic double-
stranded DNA virus, and its high-risk genotypes, including HPV-
16 and -18, are associated with cancer of the uterine cervix and
other genital cancers (Bosch et al, 2002; Zur Hausen, 2002).
Human papillomavirus is also reported to be detected in lung
carcinomas (LCs). A recent review (Syrja ¨nen, 2002) of all the
studies reported until 2001 showed that HPV was detected in 536
out of 2468 (22%) bronchial carcinomas.
The carcinogenic mechanism of HPV in genital cancers involves
molecular alterations caused by its oncogenic products, such as E6
and E7, whose expressions are regulated by cis-acting elements
in upstream regulatory region (Howley and Lowy, 2001). The E6
protein of HPV interacts with the p53 tumour suppressor protein
and an E6-associated protein, a host cell ubiquitin ligase, and
induces accelerated proteasomal degradation of p53 (Barbosa,
1996). Another study showed an inverse relationship between the
presence of HPV DNA and abnormal p53 accumulation in LCs
(Soini et al, 1996). However, the overexpression of p16
INK4a is
known to be observed in cancers of the uterine cervix (Schorge
et al, 2004), which are almost always associated with HPV infection
(Bosch et al, 2002). More importantly, high-risk HPV was
associated with a stronger expression of p16
INK4a than low-risk
HPV (Sano et al, 1998). The binding of HPV E7 with p105Rb is
considered to result in the release of E2F factors, which induces the
high level of expression of p16
INK4a (Khleif et al, 1996).
In cervical cancer, the loss of the functional E2 gene is known to
be one of the major genetic changes facilitating transformation and
the transition into a malignant state (McBride et al, 1991; Hoppe-
Seyler and Butz, 1994). In general, high-risk HPVs were frequently
found to be integrated in cervical cancer and low-risk HPVs were
frequently found to be episomal in benign lesions (Hudelist et al,
2004). In cervical cancer, integration of high-risk viral DNA into
the host genome is an important but not essential event promoting
carcinogenesis (Ho et al, 2006). When HPV integration occurs, it
promotes disruption of the HPV E2 gene, leading to abnormal
expression of E6 and E7 oncoproteins (Arias-Pulido et al, 2006).
A Chinese study examining oesophageal squamous cell carci-
nomas (SQCs) showed that only 9% out of 35 HPV-16-positive
specimens exclusively harboured the episomal form, whereas the
remaining 91% contained either only the integrated form (6%) or a
mixture of episomal and integrated forms of viral molecules (86%).
Among the 30 cancer specimens carrying mixed integrated and
episomal forms, 28 had E2/E6 ratios of less than 1, indicating
the presence of an integrated form of viral genes in these lesions
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s(Si et al, 2005). Human papillomavirus can also be detected in
cancers of the upper aerodigestive tract, including cancers of the
oral cavity, larynx, and oesophagus tract. A study in Finland
(Koskinen et al, 2003) reported HPV integration in cancers of the
hypopharynx, larynx, tongue, and oral cavity. To our knowledge,
no study has addressed the question as to whether HPV detected in
LC exists in an episomal form or in an integrated form.
In the present study, we examined lung SQCs and adenocarci-
nomas (Acs) for HPV presence. Using real-time PCR (Peitsaro
et al, 2002), we determined the HPV-16 load in SQCs and the
integration status. To our knowledge, this is the first LC study to
examine HPV viral load and integration in lung cancer specimens.
In addition, we analysed the expression of the p16
INK4a and p53
proteins using immunohistochemistry.
MATERIALS AND METHODS
Study subjects
We examined 69 bronchoscopic biopsy specimens of paraffin-
embedded tissue of SQCs (N¼37) and ACs (N¼32) of the lung,
diagnosed in the Hospital Salvador, Santiago, Chile during the
period between 1998 and 2003. According to the 1982 WHO
classification of lung tumours, LC can be classified into four broad
categories: SQCs, ACs, small cell carcinomas (SCCs), and large cell
carcinomas (World Health Organization, 1982). In the present
study, histological classification was made using the guideline of
the Japan Lung Cancer Society (The Japan Lung Cancer Society,
2000), which follows the WHO classification. In addition, as
positive control, we examined 20 carcinomas of the uterine cervix
(18 SQCs and 2 adenosquamous cell carcinomas), diagnosed at
Hospital Salvador in Santiago, Chile in 2000. Mean age and
standard deviation of these cases were 52.1 and 17.0 years,
respectively. The institutional review board of the Kagoshima
University Graduate School of Medical and Dental Sciences of
Japan approved the present study.
Polymerase chain reaction, Southern blot and sequencing
Sections (10mm) of each formalin-fixed paraffin-embedded sample
were prepared. We used 1–5 sections for each sample. The
samples were added with 1ml of xylene, and then with 1ml of
ethanol. After centrifugation, the pellet was resuspended in
digestion buffer (50mM Tris-Cl pH 8.0, 1mM EDTA pH 8.0, 0.5%
Tween 20) containing 200mg of proteinase K (Invitrogen Corp,
Carlsbad, CA, USA) and incubated during 24h at 561C. Then the
solution was heated at 1001C for 10min and centrifuged at
10000r.p.m. for 10min. Phenol–chloroform extraction was made
in all the samples and the DNA was precipitated with double
volumes of ethanol. The DNA was quantified using ND-1000
Spectrophotometer (Nano Drop Technologies, Wilmington, USA).
Since the quantity of tissue embedded in the paraffin blocks was
variable between samples, b-globin amplification was made for all
the samples to check the presence of PCR amplification inhibitors
and of amplifiable DNAs. b-Globin amplification with a set of
PCO3/PCO4 primers (Takara, Otsu, Japan) was conducted under
the following PCR conditions: initial denaturation at 951C for
4min, 40 cycles with the cycling profile of 951C for 1min, 521C for
1min and 721C for 2min and final extension for 5min at 721C. All
the samples were positive for a fragment of the b-globin gene.
Human papillomavirus amplification with GP5þ/GP6þ primers
(De Roda Husman et al, 1995) was made in a reaction mixture that
contained 2.5ml of template DNA, 200mM dNTP, 0.5mM of each
primer and 1.0U Taq DNA polymerase (Takara) in a total volume
of 25ml of reaction buffer (50mM KCl, 20mM Tris-Cl, pH 8.3). The
conditions of amplification were as follows: initial denaturation at
951C for 4min; subsequent 45 cycles at 951C for 1min, 401C for
2min and 721C for 1.5min and final extension at 721C for 5min.
HPV-6 and -18 full genomes (kindly given by Dr H zur Hausen,
Germany) were used as the external positive control. The amplified
products were confirmed through electrophoresis with 3.0%
agarose gel. Previous to the sequencing, Southern blot was
conducted to confirm the identity of amplified fragments and to
increase the sensitivity of detection of amplified fragments. As for
HPV probes, we used cloned PCR products of the HPV-positive
DNAs, which were kindly given by Dr H zur Hausen, Germany,
after purification of the PCR products from agarose gel by QIAEX
II Extraction Kits (Qiagen GmbH and Qiagen Inc., Hilden,
Germany). The ECL direct labelling and detection kit (Amersham,
Buckinghamshire, UK) was used according to the manufacturer’s
instructions. An ECL-labelled HPV18/GP5þ/GP6þ fragment was
used to detect high-risk HPVs and an ECL-labelled HPV6/GP5þ/
GP6þ fragment was used to detect low-risk HPVs. Because the
generic HPV18 and -6 probes were used, low stringency conditions
were used in the hybridizations and washes. The DNA was
transferred onto a Hybond Nþ nylon transfer membrane
(Amersham) by capillary blotting using 0.4 N NaOH. The
hybridization was made at 421C overnight and then the
membranes were washed at 421C with solution containing 6 M
urea, 0.4% SDS and 0.5 X SSC buffer. The samples that showed
visible bands in the Southern blot procedure but not in the agarose
gel electrophoresis were amplified again using 1/100 dilution of
the first PCR product using GP5þ/GP6þ protocol in 30 cycles.
Negative controls were used to confirm no carryover of amplicons.
After double PCR using GP5þ/GP6þ primers, the obtained
fragments were purified and sequenced to examine the genotype of
additional HPV-positive samples by Southern blot analysis. In all
the steps, technical considerations were taken, to avoid carrying-
over and contamination with previous amplicons in the tubes.
The HPV genotyping was made using DNA sequencing.
Amplified PCR products that appeared as a visible band after
ethidium bromide staining were purified using the QIAGEN PCR
purification kit and were directly sequenced by fluorescent dye-
labelled dideoxynucleotides and cycle sequencing methods using
the Big DyeTerminator Cycle Sequencing Kit (PE Applied
Biosystems, Foster City, USA). Sequence analysis was performed
on the ABI PRISM 310 Genetic Analyser (PE Applied Biosystems).
The nucleotide sequences were aligned and compared with those of
known HPV types available through the GenBank database (National
Institute of health, USA) by using BLAST 2.2 (http://www.ncbi.nih.
gov/BLAST/) and ClustalW (http://clustalw.genome.jp/) software
servers.
Immunohistochemistry for p16, p53, and HPV-16/18 E6
The paraffin-embedded samples were cut in 2–3mm-thick slices,
deposited in coated glass slides, and dewaxed using xylene. After
rinsing with ethanol, the slides were incubated 30min in 0.3%
H2O2/methanol and 5min in microwave at 951C in 0.01 M sodium
phosphate/citrate buffer (pH 8.0). In order to block the nonspecific
binding of the antibody, the slides were incubated for 30min with
5% bovine seroalbumin (BSA) in PBS at room temperature. A
1/200 dilution in 5% BSA–PBS of monoclonal anti-p16
INK4a
antibody was used (BD PharMingen, San Jose, USA). The slides
were incubated overnight at 41C, washed with PBS, and then
incubated with biotinylated horse anti-mouse Ig-G for 30min
followed by washing with PBS and incubation with 1:50 dilution of
the avidin–biotin–peroxidase complex (Vectastain Elite ABC kit,
Vector Laboratories, Burlingame, USA) for 30min at room
temperature. The reaction was visualized by adding diamino-
benzidine (Dako Corporation, Carpinteria, USA) for 10min. The
sections were counterstained with hematoxylin and visualized.
Negative reaction was considered when 0–9% of the cells were
stained. Positive reaction was considered when 10–100% of the
cells were stained, according to criteria reported previously (Cheng
HPV16 integration in lung carcinomas
F Aguayo et al
86
British Journal of Cancer (2007) 97(1), 85–91 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
set al, 2003). For p53 and HPV-16/18 E6 immunostaining, the
procedure was the same as it was for p16
INK4a, but primary
antibodies of p53 (1:50 dilutions) and HPV-16/18 E6 (1:50
dilutions) were used (DO-7, Dako Japan Co. Ltd., Kyoto, Japan,
and C1P5, Santa Cruz Biotechnology Inc., Santa Cruz, USA,
respectively). The interpretation of the positive signal was the
same as that used for p16
INK4a immunostaining.
Real-time PCR
To estimate viral load and to determine the integration status of
HPV-16, real-time PCR was performed with the ABI Prism 7000
Sequence Detection System and TaqMan Universal PCR Master
Mix (Applied Biosystems, Roche Molecular Systems, Foster City,
USA). All but one the HPV-16-positive specimens confirmed by
DNA sequencing were subjected to the analysis. The analysis of the
remaining one sample was not possible because its paraffin-
embedded tissue specimens were exhausted. The amplification
conditions were 2min at 501C, 10min at 951C, and a two-step cycle
of 951C for 15s and 601C for 60s for a total of 45 cycles (Peitsaro
et al, 2002). The primers used were: E6F: gagaaactgcaatgtttcaggacc
and E6R: tgtatagttgtttgcagctctgtgc, E2F: aacgaagtatcctctcctgaaattattag
and E2R: ccaaggcgacggctttg that amplify a fragment of 81 and
76bp of E6 and E2 ORFs, respectively (Peitsaro et al, 2002). We
used the E6F/R primer set for viral load and both E2F/R and
E6F/R primer sets for integration detection. The probes used were
caccccgccgcgacccata for E2 and caggagcgacccagaaagttaccacagtt
for E6 (Peitsaro et al, 2002). Both E2 and E6 probes were labelled
with FAM at the 50 end and with TAMRA at the 30 end (Applied
Biosystems Japan Ltd., Tokyo, Japan). The PCR amplification was
performed in a 25ml volume containing TaqMan 2  PCR Master
Mix with 0.5mM of E2- or E6-specific primers, 100nM of dual-
labelled E2 or E6 fluorogenic hybridization probe, and 1ml of DNA
template. For specificity and validity testing, DNAs from SiHa celll
line (Mincheva et al, 1987), which is known to contain one HPV-16
copy or two per cell, were also examined as templates. Two
standard curves for the E2 and E6 fragments were made by
amplification of dilutions between 862 million to 86 copies of
HPV-16 cloned in pUC19 plasmid (kindly given by Dr Massimo
Tommasino, IARC, France). There was a linear relationship
between the threshold cycle values plotted against the log of
the copy number over the entire range of dilutions. All the
experiments were made in duplicate.
PCR amplifications were observed correctly when the target
strains were used as templates. The primers and probes did not
increase the fluorescence with the mismatched strains (data not
shown).
In order to determine the physical status of HPV-16, the ratio
of E2 to E6 copy numbers was calculated (Peitsaro et al,
2002). Since E2 is degraded when HPV is integrated (Jeon and
Lambert, 1995) into cellular genome, E2/E6 ratio nearly equal to 1
indicates the presence of the episomal form only. Values less than
1 indicate the presence of both integrated and episomal forms,
while a ratio of 0 indicates that the fragment was not detected after
45 cycles of amplification and that HPV exists in the integrated
form only.
We also conducted real-time PCR for b-globin (110bp) to
determine the genome equivalent present in each sample and to
normalize samples for genomic DNA content. A 10-fold dilution
series of a human DNA control (Dynal UK Ltd, Wirral, UK) was
used to generate the standard curve for b-globin. The amount of b-
globin DNA present in each sample was divided by the weight of
one genome equivalent (i.e. 6.6pgcell
 1) and a factor of 2 (since
there are two copies of b-globin DNA/genome equivalent) to
obtain the number of genome equivalents in each sample. Viral
load in each specimen was expressed as the number of HPV
copies/genome equivalent or cell.
Statistical analysis
Fisher’s exact test was used to examine the statistical significance
of the results. P-values presented are two sided.
RESULTS
We examined 37 SQCs and 32 ACs of the lung diagnosed in
Santiago, Chile. Their clinicopathological features are summarized
in Table 1. Squamous cell carcinomas were more common among
men than among women (P¼0.007), and also more common
among smokers (P¼0.013). The frequency of p16
INK4a or p53
expression did not show any significant difference between SQCs
and ACs. The expression of p16
INK4a was positive in 24 out of 30 in
well- or moderately differentiated SQCs but in only 1 out of 6
poorly differentiated SQCs (P¼0.008). Such a difference was not
observed in ACs. The expression of p53 was related to tumour
differentiation in neither SQCs nor ACs.
The results of HPV detection and genotypes determined by DNA
sequencing in LC are summarized in Table 2. Human papilloma-
virus was detected in 17 (46%) and 3 (9%) of SQCs and ACs,
respectively. The difference of HPV prevalence between SQCs and
ACs was statistically significant (P¼0.001). This difference was
mainly accounted for by high-risk HPVs, which were detected in
16 SQCs and in 1 AC. Human papillomavirus presence was not
related to gender, age, or smoking habits (data not shown). Even
when age was divided into finer categories, we could not observe
any evident relationship between age and HPV presence. The
expression of p16
INK4a or p53 showed no significant difference
between HPV-positive and -negative LCs, either.
As shown in Table 2, the most frequent HPV genotype was
HPV-16, which was detected in 10 SQCs and 1 AC. In addition, we
analysed 18 SQCs and 2 adenosquamous cell carcinomas of the
Table 1 Clinicopathological features of lung SQC and AC
Number of subjects (%)
SQC AC P-value*
Total 37 (100) 32 (100)
Gender 0.007
Male 32 (86) 18 (56)
Female 5 (14) 14 (44)
Age (years) 0.415
 64 12 (32) 15 (47)
65  20 (54) 15 (47)
75+ 5 (14) 2 (6)
Smoking 0.013
Non smoker 2 (5) 10 (31)
Smoker 29 (78) 20 (63)
Unknown 6 (16) 2 (6)
Tumour differentiation 0.441
Well 8 (22) 7 (22)
Moderate 23 (62) 16 (50)
Poor 6 (16) 9 (28)
P16
a 0.799
Negative ( 9%) 11 (31) 11 (34)
Positive (10% ) 25 (69) 21 (66)
P53
a 0.809
Negative ( 9%) 20 (56) 19 (59)
Positive (10% ) 16 (44) 13 (41)
SQC¼ squamous cell carcinoma; AC¼adenocarcinoma. *P-values for difference
between SQCs and ACs were obtained from Fisher’s exact test.
aExpression of p16
and p53 was not examined in one SQC because of the shortage of tissue sample.
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suterine cervixes from Chile, using the same methodology as shown
in Table 2. Among the 18 SQCs, there were 11 well- or moderately
differentiated SQCs and 7 poorly differentiated SQCs. Human
papillomavirus was detected in 19 out of 20 (95%) cervical cancer
samples. We could not detect HPV genome in one case with
adenosquamous cell carcinoma. All the HPV-positive cases
harboured high-risk HPVs, including HPV-16. In two HPV-16-
and one HPV-59-positive cases, we also detected the low-risk type
HPV-6/11.
We conducted real-time PCR analysis to estimate viral load and
to determine the integration status of HPV-16 (Table 3). All but
one the HPV-16-positive specimens were subjected to the analysis.
The analysis of the remaining one sample was not possible because
its paraffin-embedded tissue specimens were exhausted. The
validity of the assays was confirmed by accurate quantification
of viral copy numbers (one copy per cell) from SiHa cell line,
which is known to contain one HPV-16 copy or two per cell. The
median viral loads of lung SQCs and cervical cancer specimens
were 8.2 and 64254 copies per nanogram of DNA, respectively.
SiHa cell line had 144 E6 copies per nanogram of genomic DNA.
Most of the lung SQCs examined had E6 copies less than this
figure. However, there was one case (LC-5) having E6 copies per
cell as large as 8479, a much larger figure than that of SiHa cell line.
The case LC-5 was a 75-year-old male smoker, and the tumour was
well-differentiated type SQCs with p16
INK4a and p53 expression in
10 and 70% of tumours, respectively. We also examined 7 out of 12
HPV-16-positive cervical carcinomas, and three of them had E6
copy numbers lower than that of the case LC-5. Viral load was not
related to any clinicopathological features examined (data not
shown).
E2/E6 ratios are presented in Table 3. All the cervical cancer
cases had an E2/E6 ratio less than 0.02, indicating to harbour
integrated HPV-16. In LC cases, there were two cases (LC-1 and -5)
where E2 could not be detected and four cases where E2 copy
number was lower than detectable level, less than 1 10
 6ng
DNAml
 1. Those six LC cases were considered to have only
integrated form of HPV. On the other hand, there were two cases
where E2/E6 ratio was 0.01–0.02 and considered to have both
integrated and episomal forms of HPVs (integration status:
mixed). The remaining one case had the E2/E6 ratio of about
one, suggesting the episomal form.
We also examined the E6 expression among 14 HPV-16/18-
positive cases by immunohistochemistry. There were only two SQC
cases (13%) showing the E6 expression, and both of them were
HPV-16 positive (Table 3). Case LC-5, having the highest viral
load, did not show E6 expression. The E6 expression was observed
in the cytoplasm of partial tumour cells (Figure 1). Neither the
copy number of E6 nor HPV-integration status was related to the
E6 expression (Table 3). These E6-positive SQCs were negative for
p53 expression.
Table 2 HPV detection in lung and cervical cancers
Number of subjects (%)
Cervical
Lung cancer
cancer SQC AC P-value
a
Total 20 (100) 37 (100) 32 (100)
HPV positive cases
All HPV genotype 19 (95) 17 (46) 3 (9) 0.001
High-risk HPV*
HPV-16 12 (60) 10 (27) 1 (3) 0.008
HPV-18 2 (10) 3 (8) — 0.243
HPV-31 — 1 (3) — 1.000
HPV-33 1 (5) — —
HPV-45 3 (15) 2 (5) — 0.495
HPV-59 1 (5) — —
Low-risk HPV*
HPV-6 — 1 (3) 2 (6) 0.593
HPV-6/11 3 (15)
b ——
HPV¼human papillomavirus; SQC¼squamous cell carcinoma; AC¼adenocarcinoma.
*Classification of high- and low-risk HPV genotypes was based on the report by
Munoz et al.
aP-values for difference between SQCs and ACs of the lung were
obtained from Fisher’s exact test.
bCo-infection with high-risk HPV was observed in
two SQCs (moderately or poorly differentiated) and one adenosquamous cell
carcinoma.
Table 3 HPV-16 viral load, physical status, and immunostaining for E6 in lung SQCs and cervical carcinomas
Viral load Integration Immunohistochemistry
E6/ng of DNA HPV-16 copies/cell E2/E6 Status HPV-16/18 E6
a p16
a p53
a
Lung cancer
LC-1 4 10
 2 1 10
 7 No E2
b Integrated   +  
LC-2 51 0.1 0.02 Mixed   +  
LC-3 74 0.3 0.01 Mixed   +  
LC-4 4 0.4 o1 10
 6 Integrated +   
LC-5 8479 217 No E2
b Integrated   ++
LC-6 207 1 o1 10
 6 Integrated   +  
LC-7 1 0.01 o1 10
 6 Integrated   +  
LC-8 4 1 o1 10
 6 Integrated   ++
LC-9 8.2 1 10
 4 1.06 Episomal + +  
Cervical cancer
CX-3 79827 29174 0.02 Mixed
CX-5 64254 372 0.02 Mixed
CX-6 609392 425 0.02 Mixed
CX-8 3495 1 0.02 Mixed
CX-9 3356 2650 o1 10
 6 Integrated
CX-10 105292 754 3 10
 3 Mixed
CX-11 5527 30 0.02 Mixed
SiHa cell line 144 1 o1 10
 6 Integrated
aHPV-16/18 E6, p16, and p53 expressions were not examined in cervical carcinomas.
bHPV-16 E2 was not detected by TaqMan real-time PCR.
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sDISCUSSION
In the present study, we detected HPV in 46% of SQCs but in only
9% of ACs of the lung. The difference between SQCs and ACs was
highly significant (P¼0.001). Among HPV genotypes detected,
85% were high-risk HPV. The most frequently detected genotype
in the present study was HPV-16, which accounted for 55% of
HPV-positive cases, as was also the case in our previous study
conducted in other Latin-American countries, including Mexico,
Colombia, and Chile (Castillo et al, 2006). Our findings are also in
accordance with those shown in a review published by Syrja ¨nen
(2002), where HPV was positive in 25% of SQCs, 19% of SCCs, and
8% of ACs.
Physical status of HPV was determined by HPV E2/E6 ratio in
the present study, and most of the HPV-16-positive SQCs were
considered to have HPV-16 in the integrated form, and about half
of the integrated HPV-16 was accompanied by episomal HPV-16.
Note, however, that this approach first reported by Peitsaro et al
(2002) does not directly show the presence of integrated HPV in
the cellular genome by, for example, its sequencing. However, our
observation that E2/E6 ratio did not become larger than the unity
indirectly supports the validity of this approach.
Although the viral loads of most LCs were low, one case showed
the viral load of HPV-16 as high as 8479ng
 1 DNA, which was
even higher than minimum viral load of the seven cervical
carcinomas (viral load: 3356–609392 per nanogram DNA)
examined in the present study. Since SiHa cell line, having 1–2
HPV copies per cell, was found to have 144 copies per nanogram
DNA in our analysis, this LC case is suspected to have HPV copies
much more than 1–2 per cell.
If a clonal expansion occurs after HPV infection in lung
epithelial cells, HPV is expected to be found in all the carcinoma
cells. However, our results suggest that this scenario is unlikely
because only a very small proportion of the malignant cells are
integrated. Regarding the role of HPV in LCs, Kinjo et al (2003)
has argued that HPV is not aetiologically involved in LC
development but that HPV induces squamous metaplasia in ACs.
Another possible explanation for such a low viral load may suggest
a ‘hit-and-run’ mechanism, where the virus DNA may be lost after
transformation, as shown in studies on a bovine model, and as
suggested in HPV-18 oncogenesis and in non-melanoma skin
cancer developments mediated by HPV (Iwasaka et al, 1992; Aubin
et al, 2003).
The integration of HPV in the LC genome does not necessarily
mean that HPV is involved in the development of lung cancer. In
order to examine the expression of proteins that are considered to
be associated with altered signal pathways in cervical cancer, we
compared the expression of suppressor genes in HPV-positive and
-negative LCs. In cervical carcinomas, p16
INK4a is known to be
upregulated by HPV (Ishikawa et al, 2006). In the present study,
however, p16
INK4a was expressed in more than 80% of lung SQC
cases regardless of HPV presence and we could not find any
evidence suggesting p16
INK4a upregulation by HPV in LCs. A study
reported by Geradts et al (1999) has shown that about 50% of
non-small cell LCs are with positive p16
INK4a expression, which
was defined as a diffuse or mosaic pattern throughout a tumour.
They also pointed out variable p16
INK4a-positive frequencies in
different reports, possibly due to genetic backgrounds, environ-
mental factors, biological heterogeneity, and/or technical differ-
ences. Therefore, it seems difficult to make comparison between
different studies. In our previous study of gastric cancer in Japan,
60% of them were p16
INK4a positive (Koriyama et al, 2004). Taken
together, LCs may have higher p16
INK4a expression than other
cancers. In the case of cervical cancer, the p105Rb is sequestered
and degraded by HPV E7, causing the release of E2F protein, which
in turn leads to p16
INK4a upregulation. In LC, other mechanisms
may be at work.
The p53 gene is reported to be frequently mutated in lung
SQCs (Sanchez-Cespedes, 2003), and missense mutations fre-
quently cause the abnormal accumulation of p53 (Toyooka
et al, 2003). A large-scale study showed that about 52% of lung
SQCs was p53 positive (Tammemagi et al, 1999). In the present
study, p53 was positive in less than 50% of carcinomas regardless
of HPV presence. When the proportion of p53-positive cells in
each carcinoma was examined (data not shown), we found no
difference between HPV-positive and -negative SQCs. The
HPV-16/18 E6 protein has been reported to interact with p53
and target it for degradation through an ubiquitin-dependent
pathway (Scheffner et al, 1990). Although the number of
E6-positive cases was small in the present study, all of them were
p53 negative.
It is suspected that HPV was more strongly associated with well-
differentiated SQCs, featured by conspicuous pearl formation, than
less-differentiated SQCs (Miyagi et al, 2000). A Greek study also
showed such an association (Papadopoulou et al, 1998). We also
observed pearl formation in 4 out of 8 well-differentiated SQCs
(50%). However, two of them were HPV-16 positive and the rest
were HPV negative (data not shown).
A large study on numerous fresh frozen LCs in West-European
countries found a low prevalence of HPV16 and a very low viral
load without any HPV16 E6 mRNA expression (Coissard et al,
2005). On the other hand, studies in Latin-American and Asian
LCs reported relatively high prevalence of HPV, including HPV16
(Miyagi et al, 2000, Castillo et al, 2006) even though they used
formalin-fixed paraffin-embedded carcinoma specimens.
The DNA specimens extracted from paraffin-embedded blocks
are known to be frequently degraded into 200bp long or even
shorter fragments (Ben-Ezra et al, 1991; Karlsen et al, 1994). For
this reason, we used GP5þ/GP6þ primers for PCR to detect
a short fragment from the L1 region of HPV (155bp) (De Roda
Husman et al, 1995). In addition, all of the samples we examined
were b-globin positive, which is 110bp. In the present study,
amplified products by PCR were analysed by Southern blot
hybridization using the ECL-labelled probes obtained from cloned
GP5þ/GP6þ amplified products of HPV-positive control DNAs.
When compared to PCR-agarose gel electrophoresis and in situ
hybridization (data not shown), our method is considered to be
more sensitive and enables us to detect HPV even when carcinoma
cells have a small number of HPV copies. However, it is not
possible for us to tell whether HPV is present in tumour or normal
cells because most tissue specimens contained adjacent normal
cells. Further studies using the microdissection technique are
necessary to address this question.
Figure 1 HPV-16/18 E6 immunostaining. The E6 expression was
observed in cytoplasm of tumour cells ( 200).
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uterine cervix, HPV-18 has been shown to have a higher risk of
developing Acs, while HPV-16 is more strongly associated with
SQCs (Castellsague et al, 2006). In the case of the lung, the
association of HPV-18 with ACs was shown by a study of non-
smoking Taiwanese women (Cheng et al, 2001). A Latin-American
study also detected HPV-18 only in lung ACs (Castillo et al, 2006).
A recent meta-analysis by Chen et al (2004) showed that 9–42% of
pulmonary ACs among Asians were HPV positive. However, HPV-
18 was not detected exclusively in ACs. For example, a North
American study reported by Bohlmeyer et al (1998) detected HPV-
18 in 2 out of 34 lung SQCs. Interestingly, their study did not find
any other HPV genotypes. Another study, conducted in China,
detected both HPV-16 and -18 in ACs of the lung at similar
frequencies (Fei et al, 2006). At this moment, it is difficult to
postulate that HPV-18 is more strongly related to ACs than SQCs
of the lung.
The transmission route of the HPV detected in LCs is as yet
unclear. Studies on HPV infection and cancers of the oral cavity,
oesophagus and lung suggested the possibility of sexual transmis-
sion (Smith et al, 2004). Recent studies in Taiwan detected
identical sequences of L1 and E6 of HPV16/18 in LCs and blood
cells. In addition, female lung cancer patients showed a correlation
between HPV16/18 detection frequencies in LCs and cervical
smears (Chiou et al, 2003). Those findings suggest that HPV
detected in LC may originate in the uterine cervix and spread to
lung tissue via the bloodstream. However, a recent study in Latin
America, which compared the second cancer risk of 335 women
with invasive cervical cancer and their first degree relatives, did
not find any increase in LC risk among cervical cancer patients
(Weber et al, 2005).
In summary, high-risk HPV, including HPV-16, was detected in
Chilean SQC cases at a high frequency, and the real-time PCR
analysis suggested the integration of HPV-16 into the cellular
genome of SQC specimens. Although the viral load was in general
very low and HPV E6 expression is none or weak, further studies
seem warranted to examine aetiological involvement of high-risk
HPV in lung carcinogenesis.
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